Trending Healthcare Stocks Overview: Sagent Pharmaceuticals Inc (SGNT), Aerie Pharmaceuticals Inc (AERI)


Sagent Pharmaceuticals Inc (NASDAQ:SGNT):

Stock’s Trading Stats:

Sagent Pharmaceuticals Inc (NASDAQ:SGNT) surged 9.98% yesterday and closed at $13.56. The company’s market capitalization is at $215.86 Million with an average trading volume of 339,732.00. The total number of Outstanding Shares Held by the company are 32.84 Million.

Recent Press Release:

Sagent Pharmaceuticals, Inc. (SGNT) develops, sources, manufactures, and markets injectable pharmaceuticals in North America. The company offers anti-infective products, such as Cefepime, an antibiotic used to treat infections of the urinary tract, and skin and skin structures, in addition to moderate to severe pneumonia, intra-abdominal infections, and as empiric therapy for febrile neutropenic patients; and Levofloxacin, a fluoroquinolone antibacterial for the treatment of infections caused by susceptible bacteria, counting nosocomial and community attained pneumonia, sinusitis, chronic bronchitis, skin and skin structure infections, prostatitis, urinary tract infection, and pyelonephritis in adults of age 18 years or older. It also provides oncology products compriseing of Leucovorin Calcium, a folic acid derivative used to prevent harmful effects of methotrexate when methotrexate is used to treat cancer; and Zoledronic Acid, a bisphosphonate given intravenously to prevent skeletal fractures in patients with multiple myeloma and prostate cancer, in addition to for treating osteoporosis. In addition, the company offers critical care products comprising Heparin, an anticoagulant used to prevent and treat blood clotting during and after surgery and dialysis; and Propofol, a sedative used to induce and maintain general anesthesia during surgical procedures. As of December 31, 2015, its product portfolio comprised of 55 marketed products in an aggregate of 181 presentations, in addition to 48 products in an aggregate of 98 presentations in the United States. Sagent Pharmaceuticals, Inc. sells its products to hospitals, integrated delivery networks, and alternative site facilities through pharmaceutical wholesalers and specialty distributors.

Aerie Pharmaceuticals Inc (NASDAQ:AERI):

Stock’s Trading Stats:

Aerie Pharmaceuticals Inc (NASDAQ:AERI) closed at $16.00 yesterday by showing an increase of 4.85%. The total number of outstanding shares held by the company are 26.51 Million with the total market capitalization of $421.15 Million. The number of shares traded on the last trading session are 535,616.00.

Recent Press Release:

Aerie Pharmaceuticals, Inc. (AERI) on April 5, 2016 declared that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at 3:00 p.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update.

The presentation will be webcast live and may be accessed by visiting Aerie’s website at A replay of the webcast will be accessible for 10 business days.

Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie’s two lead product candidates are once-daiIy IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma and ocular hypertension. It is predictable that the NDA filing for RhopressaTM (netarsudil ophthalmic solution) 0.02% will take place in the third quarter of 2016. The second product candidate, RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of RhopressaTM and widely prescribed PGA latanoprost, presently has two Phase 3 registration trials underway, named Mercury 1 and Mercury 2. If these trials are successful, a RoclatanTM NDA filing is predictable to take place in the second half of 2017. In addition, Aerie is further building its pipeline, counting through research collaborations with GrayBug, Inc. and Ramot at Tel Aviv University.